Гефитиниб-промомед - analogs
Components: Gefitinib |
|||||||||
Pharmgroups: Antitumor agents - protein kinase inhibitors || Antitumor drugs other |
|||||||||
| Prices in pharmacies: — Instructions Гефитиниб-промомед | |||||||||
|
ⓘ✘Enter drugs for checking interactions through a quick button search . Pembrolizumab ✘ (incl) Sabal-homaccord ✘ (incl) Эдас-141 ✘ (incl) YOUNGLIFE ✘ (incl) Dornase alfa ✘ (incl) Episindan ✘ (incl) Sulfamonomethoxine ✘ (incl) Remifentanil ✘ (incl) Antraliv ✘ (incl) Фиточай «Сустафитол» ✘ (incl) Азитромицин-Розлекс ✘ (incl) Rubiae tinctorum extract ✘ (incl) Famosan ✘ (incl) Glaucine+Ephedrine+[Salvae oil] ✘ |
|
ⓘ✘ diseases to evaluate contraindications and side effects through a quick search. | ||||||
Начиная работу с сервисом, вы принимаете соглашение пользователя. Kiberis do not replace the doctor!
| Similar | Complete analog ⓘ✘Analogues of the drug with completely identical active ingredients |
Prices in pharmacies |
| ≈100% | neutral Gefitinib | 578.2€ |
| ≈100% | neutral Iressa | 1114€ |
| ≈100% | neutral Gefitinib-nativ | — |
| ≈100% | neutral Gefitinib-TL | — |
-
Similar
Prices in
pharmaciesAnalogs by action ⓘ✘Analogues of the drug according to its degree of similarity with other drugs that are not direct analogues
- 50% — Афатиниб neutral [Afatinib]
- 50% — Афатиниб-промомед neutral [Afatinib]
- 50% — Афатиниб Фармасинтез neutral [Afatinib]
- 46% 3369.2€ Tagrisso neutral [Osimertinib]
- 46% — Осимертиниба мезилат neutral [Osimertinib]
- 46% — Zykadia neutral [Ceritinib]
- 46% — Табректа neutral [Capmatinib]
- 46% — Осимертиниб-АМЕДАРТ neutral [Osimertinib]
- 46% — Осимертиниб-Промомед neutral [Osimertinib]
- 46% — Осимертиниб Фармасинтез neutral [Osimertinib]
- 42% — Мектови neutral [Binimetinib]
- 40% 906.5-1079.2€ Giotrif neutral [Afatinib]
- 39% 2560.7-2855€ Xalkori neutral [Crizotinib]
- 39% — Алектиниб-АМЕДАРТ neutral [Alectinib]
- 39% — Кризотиниб-Промомед neutral [Crizotinib]
- 36% — Эрибулин-АМЕДАРТ neutral [Eribulin]
- 36% — Эриблиус neutral [Eribulin]
- 35% 1050€ Mekinist neutral [Trametinib]
- 35% 960€ Risarg neutral [Ribociklib]
- 35% — Осимертиниб neutral [Osimertinib]
- 35% 1750€ Tafinlar neutral [Dabrafenib]
- 35% 2538.7€ Alecensa neutral [Alectinib]
- 35% — Лапатиниба дитозилат моногидрат neutral [Lapatinib]
- 35% — Erlotinib hydrochloride neutral [Erlotinib]
- 35% — Витракви neutral [Larotrectinib]
- 35% 630-1550€ Cotellic neutral [Cobimetinib]
- 35% — Рецевмо neutral [Selpercatinib]
- 35% 899.2-1145€ Tyverb neutral [Lapatinib]
- 34% — Tarlenib neutral [Erlotinib]
- 33% 2725€ Caprelsa neutral [Vandetanib]
- 33% — Акдайна neutral [Capivasertib]
- 32% — Бозутиниб-химрар neutral [Bosutinib]
- 32% 838€ Tarceva neutral [Erlotinib]
- 32% — Бозутиниб neutral [Bosutinib]
- 32% — Бозутиниб-промомед neutral [Bosutinib]
- 32% — Вандетаниб-промомед neutral [Vandetanib]
- 32% — Бозутиниб-ДЖИЭФСИ neutral [Bosutinib]
- 32% — Бозутиниб Фармасинтез neutral [Bosutinib]
- 31% 395-452€ Erlotinib - native neutral [Erlotinib]
- 31% — Эрлатера neutral [Erlotinib]
- 31% — Эрлотиниб-тл neutral [Erlotinib]
- 31% — Рекобази neutral [Cabozantinib]
- 31% — Кабозантиниб neutral [Cabozantinib]
- 31% — Кабозантиниб Дж neutral [Cabozantinib]
- 31% — Кабозантиниб-промомед neutral [Cabozantinib]
- 31% — Арсавио neutral [Axitinib]
- 31% — Амекарб neutral [Cabozantinib]
- 31% — Ксинтабика neutral [Axitinib]
- 31% — Акситиниб-АМЕДАРТ neutral [Axitinib]
- 30% — Hexvix neutral [Hexylaminolevulinate]
Learn more about the selection of analogues
▶
- The drug has «Гефитиниб-промомед» 12 full analogs, the cheapest - Лангерра (197.3€); 51 analog by action, the most similar - Tagrisso (3369.2€).
- Medical online service has selected the best substitutes for Гефитиниб-промомед based on its instructions, components, pharmaceutical groups and practical application.
- The table shows the prices of analogues Гефитиниб-промомед to choose the cheapest pills.
- If you have introduced other drugs for registration, substitutes are selected taking into account the assessment of interactions and safety.
- Sometimes, due to the presence of dangerous interactions, it is necessary to use drugs that are similar in effect, sometimes even from different pharmacological groups.